secwatch.observer — SEC 8-K summary
======================================

Issuer:     CVRx, Inc. (CVRX)
CIK:        0001235912
Form:       8-K
Filed at:   2023-01-26T23:59:59+00:00
Accession:  0001104659-23-007029
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CVRx Q4 revenue $7.2M (+96% YoY); guides FY2023 revenue $35-38M
---------------------------------------------------------------

- Q4 2022 total revenue $7.2M, up 96% vs prior year; US HF revenue $6.0M (+121% YoY).
- Full year 2022 revenue $22.5M (+72% YoY); net loss $41.4M ($2.02 per share).
- Active implanting centers grew 130% to 106 in 2022 from 46 in 2021.
- FY2023 guidance: revenue $35-38M, gross margin 78-79%, operating expenses $76-80M.
- BeAT-HF trial unblinding and data announcement expected later in Q1 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1235912/000110465923007029/0001104659-23-007029-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1235912/000110465923007029/tm234419d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-007029

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer